Welcome to the international HTA database

Showing [24845 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	Agency for Care Effectiveness (ACE)	Atogepant and rimegepant for prophylaxis of migraine
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Perinatal pathway: supporting women in a handicap situation related to a physical disability, an intellectual disability or autism]
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Effectiveness and safety of adaptive radiation therapy in patients with lymphoma, head and neck cancer or lung carcinoma]
2025	Swiss Federal Office of Public Health (FOPH)	Multigene-expression tests for breast cancer
2025	NIHR Health Services and Delivery Research programme	Optimisation of the deployment of automated external defibrillators in public places in England
2025	Agency for Care Effectiveness (ACE)	Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025	NIHR Health and Social Care Delivery Program	Optimising the delivery and impacts of interventions to improve hospital doctors’ workplace wellbeing in the NHS: The Care Under Pressure 3 realist evaluation study
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of children with peritoneal carcinomatosis]
2025	NIHR Health Technology Assessment programme	Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Food allergen-specific IgG4 (immunoglobulin G4) measurement by immunoassay]
2025	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 1094
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy and safety of non-invasive brain stimulation therapies for the neurorehabilitation of patients with stroke]
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Blood levels testing of imatinib and its active metabolite by high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2025	National Institute for Health and Care Excellence (NICE)	Guselkumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1095
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Magnetic nanoparticles and a magnetic field generator for inducing hyperthermia in the treatment of pancreatic cancer]
2025	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2025	National Institute for Health and Care Excellence (NICE)	Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over. NICE technology appraisal guidance 1093
2025	Basque Office for Health Technology Assessment (OSTEBA)	[CT-guided percutaneous ablation for lung metastasis using radiofrequency or microwaves in patients who are not eligible for curative local and/ or systemic treatment]
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Asynchronous teledermatology as a mechanism for triage and patient referral between primary and specialty care and to support the diagnosis of dermatologic conditions]
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1092
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2025	National Institute for Health and Care Excellence (NICE)	Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments. NICE technology appraisal guidance 1091
2025	National Institute for Health and Care Excellence (NICE)	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 1090
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Autonomous diagnostic system (AI) for patients with diabetic retinopathy]
2025	National Institute for Health and Care Excellence (NICE)	Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 1089
2025	Malaysian Health Technology Assessment (MaHTAS)	Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety and efficacy of guided imagery for the control of chronic pain]
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2025	NIHR Health Services and Delivery Research programme	How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis
2025	National Institute for Health and Care Excellence (NICE)	Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. NICE technology appraisal guidance 1088
2025	Malaysian Health Technology Assessment (MaHTAS)	3D-printing for orthosis, prosthesis and exoskeleton
2025	National Institute for Health and Care Excellence (NICE)	Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of delayed antibiotic prescription in the treatment of acute upper respiratory tract infections]
2025	National Institute for Health and Care Excellence (NICE)	Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence. NICE technology appraisal guidance 1086
2025	Malaysian Health Technology Assessment (MaHTAS)	Microwave ablation for kidney and liver tumours
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025	Health Technology Wales (HTW)	Smartphone based photoplethysmography for the detection and monitoring of atrial fibrillation
2025	National Institute for Health and Care Excellence (NICE)	Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen. NICE technology appraisal guidance 1087
2025	Malaysian Health Technology Assessment (MaHTAS)	Apomorphine injection and subcutaneous infusion therapy for advanced Parkinson’s disease
2025	National Institute for Health and Care Excellence (NICE)	Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
2025	NIHR Health Technology Assessment programme	The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Technological innovations for the identification and diagnosis of neurocognitive disorders in Quebec]
2025	Malaysian Health Technology Assessment (MaHTAS)	Robotic-assisted surgery for gynaecological disorders
2025	National Institute for Health and Care Excellence (NICE)	Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 802
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
2025	NIHR Health Services and Delivery Research programme	Community and hospital-based healthcare professionals perceptions of digital advance care planning for palliative and end-of-life care: a latent class analysis
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Disinvestment]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of scalp cooling to prevent chemotherapy-induced alopecia (CIA)]
2025	NIHR Health Technology Assessment programme	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Neurocognitive disorders: an adapted path from identification to treatment]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V]
2025	Scottish Health Technologies Group (SHTG)	Vacuum bell device for people with pectus excavatum
2025	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Use of the OxyGo NEXT® Portable Oxygen Concentrator during sleep: clinical effectiveness and safety]
2025	Haute Autorite de sante (HAS)	[Targeted next-generation sequencing of gene panels for the pharmacogenetics of acute leukaemia and supportive care treatments.]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V]
2025	Scottish Health Technologies Group (SHTG)	Artificial intelligence (AI) assisted endoscopy
2025	NIHR Health Technology Assessment programme	Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Cardiac and pulmonary telerehabilitation]
2025	NIHR Health Technology Assessment programme	Process evaluation exploring implementation and delivery of a home-based extended exercise intervention for older people with frailty: the HERO trial
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2025	Scottish Health Technologies Group (SHTG)	Stability of prostate specific antigen (PSA) in blood samples
2025	NIHR Health Technology Assessment programme	Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Clinical follow-up of incidental pulmonary nodules: progress report on the selection of efficacy and safety indicators]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Technology Assessment programme	Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025	NIHR Health and Social Care Delivery Program	Remote and digital services in UK general practice 2021–2023: the Remote by Default 2 longitudinal qualitative study synopsis
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Relevance of the use of HIV rapid test kits by community workers in Québec]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Services and Delivery Research programme	The implementation of safety management systems in healthcare: a systematic review and international comparison
2025	NIHR Health and Social Care Delivery Program	After the disruptive innovation: how remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Overview of applications of extended reality technologies in health and social services]
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Patient-specific 3D-printed models in surgical planning: mapping review of clinical indications and scoping review of organizational and legal aspects]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Proton pump inhibitors: deprescription and lifestyle changes]
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[The safety, efficacy, effectiveness, efficiency, and organizational impact of mHealth tools for guided telerehabilitation that enable telemonitoring in neck pain, low back pain, and painful shoulder]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V]
2025	Health Technology Wales (HTW)	Long length peripheral intravenous catheters for patients with difficult intravenous access
2025	NIHR Health Services and Delivery Research programme	Witness to harm-holding to account. Improving patient, family and colleague experiences of fitness to practise proceedings: a mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V]
2025	Gesundheit Osterreich GmbH (GOeG)	[Efficacy and safety of antibody therapies in early-stage Alzheimer's disease]
2025	NIHR Health Technology Assessment programme	Diagnostic strategies for suspected acute aortic syndrome: systematic review, meta-analysis, decision-analytic modelling and value of information analysis
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sepiapterin (phenylketonuria) – Addendum to Project G25-23]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Bispecific and tumor-infiltrating T cell therapies: considerations for deployment in Quebec]
2025	Institute of Health Economics (IHE)	PET/CT capacity for cancer diagnosis and follow-up: rapid review
2025	NIHR Health Services and Delivery Research programme	Post-pandemic planning for maternity care for local, regional, and national maternity systems across the four nations: a mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Securing scientific research without PubMed and ClinicalTrials.gov]
2025	NIHR Health Services and Delivery Research programme	Team-based motivational engagement intervention in young people with first-episode psychosis: the EYE-2 cluster RCT with economic and process evaluation
2025	NIHR Health Technology Assessment programme	A community-based rehabilitation package following hip fracture: FEMuR III a multi-centre RCT, economic and process evaluation
2025	NIHR Health Technology Assessment programme	Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT
2025	NIHR Health Technology Assessment programme	Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis
2025	NIHR Health Technology Assessment programme	The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025	NIHR Health Services and Delivery Research programme	Integration of specialised services for eating disorders and functional symptom disorders in children and young people: discrete choice experiments and qualitative study